This book explores the latest developments in the identification of biomarkers for early diagnosis of neurodegenerative diseases and methodologies for the biophysical; in vitro; cell-based; and in vivo profiling, during the early phases of drug discovery, new hits, leads, and drug candidates directed to a variety of biological targets with key pathogenic roles in neurodegenerative diseases. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and thorough, Methods in Neurodegenerative Disease Drug Discovery offers practical guidance to researchers in the medicinal chemistry community. The methods described in this book can be readily implemented in many laboratories and will aid new and experienced researchers with creating future treatments for these devastating diseases.

Includes cutting-edge methods and protocols Provides step-by-step detail essential for reproducible results Contains key notes and implementation advice from the experts

Inhalt

Blood-Based Biomarkers for Alzheimer's Disease Diagnosis.- BACE-1 Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Identification of -Synuclein Aggregation Inhibitors via High-Throughput Screening.- TDP-43 Modulation for the Treatment of Neurodegenerative Diseases: Rationale and Assay Methodologies.- Modulation of the KEAP1-NRF2 Pathway for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Monoamine Oxidase Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Targeting Cannabinoid Receptors against Neurodegenerative Diseases: NanoLuc Binary Technology and Proximity Ligation In Situ Assay to Evaluate Pharmacological Activity of Novel Compounds and Receptors Heteromerization.- Cholinesterase Inhibition for the Treatment of Neurodegenerative Diseases: Assay Methodologies and Reference Compounds.- Use of Calcium-Sensitive Indicators for the Determination of NMDA Receptor Activity.- Cell-Based Assays to Assess Neuroprotective Activity.- Caenorhabditis elegans Models of Neurodegenerative Diseases.- A Toolkit to Model Neurodegenerative Disease in Drosophila melanogaster.- Mouse Models of Alzheimer's Disease.- Mouse Models of Amyotrophic Lateral Sclerosis.